CLSA President & CEO Mike Guerra was recently featured in the San Diego Union-Tribune commenting on employment trends in California’s life sciences sector.
“We all agree that drug prices are high, but a proposal before the Legislature would make that situation worse, even as it seeks to solve the problem.” Read more about AB 824 in CalMatters.
CLSA Board Member Wendye Robbins, MD, President & CEO of Blade Therapeutics, pens an op-ed in the San Francisco Chronicle, urging the Legislature to make key changes to Assembly Bill 824, priority legislation for CLSA that seeks to prohibit generic drug manufacturers from seeking patent settlement agreements.
CLSA was recently featured in the San Diego Business Journal regarding the expansion of its board of directors.
Did you miss our Evening with Thought Leaders program last week? Check out this BioSpace piece for a recap of the key policy issues discussed by Jim Greenwood of BIO, Janet Trunzo of AdvaMed and Melinda Richter of Johnson & Johnson Innovation | JLABS.
CLSA’s Evening With Thought Leaders Event was recently featured in the San Diego Union-Tribune.
CLSA President & CEO Mike Guerra recently sat down with Global Business Reports to discuss CLSA’s mission, as well as the commitment of our members in helping patients, while boosting investment, innovation and job creation in California’s life sciences sector.
CLSA had a chance to speak with STAT News regarding medical research community concerns with AB889, a bill that would threaten the safety of researchers and discovery of new medicines. Check out Rebecca Robbins’ interview with Oliver Rocroi, CLSA’s VP, State Government Relations.
CLSA was recently featured in the news voicing concerns with a newly proposed California law (AB 889) that would add duplicative and burdensome reporting requirements for medical researchers who utilize animal models for testing throughout the Golden State.
CLSA’s hire of Andrew Setikas was recently featured in BioSpace’s Movers & Shakers list.